These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 877518)

  • 1. Resistance to activated F IX concentrate (FEIBA).
    Stenbjerg S; Jorgensen J
    Scand J Haematol; 1977 May; 18(5):421-6. PubMed ID: 877518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII.
    Stenbjerg S; Jørgensen J
    Acta Med Scand; 1978; 203(6):471-6. PubMed ID: 665313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.
    Parry DH; Bloom AL
    J Clin Pathol; 1978 Nov; 31(11):1102-5. PubMed ID: 739057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
    Zwahlen H; Beck EA
    Acta Haematol; 1980; 64(1):12-7. PubMed ID: 6774572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
    Sjamsoedin LJ; Heijnen L; Mauser-Bunschoten EP; van Geijlswijk JL; van Houwelingen H; van Asten P; Sixma JJ
    N Engl J Med; 1981 Sep; 305(13):717-21. PubMed ID: 6790990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of patients with hemophilia A having antibodies to factor VIII].
    Lopaciuk S; Ziemski JM
    Acta Haematol Pol; 1979; 10(2):115-22. PubMed ID: 474044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
    Iizuka A; Kuwashima M; Nagao T
    Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811
    [No Abstract]   [Full Text] [Related]  

  • 8. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
    Verroust F; Moussard C; Allain JP
    Presse Med; 1985 May; 14(19):1073-6. PubMed ID: 3158962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of FEIBA and Amicar in the operating room--dental treatment of a patient with hemophilia and high titer factor VIII inhibitors.
    Sharp HK; McIlveen LP; Schuman NJ
    Spec Care Dentist; 1986; 6(5):210-2. PubMed ID: 2945270
    [No Abstract]   [Full Text] [Related]  

  • 10. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX.
    Tjønnfjord GE; Brinch L; Gedde-Dahl T; Brosstad FR
    Haemophilia; 2004 Mar; 10(2):174-8. PubMed ID: 14962207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison between a serum fraction and FEIBA fraction in haemophilia.
    Hutton RA; Dormandy K; Nour-Eldin F
    New Istanbul Contrib Clin Sci; 1980; 13(1):9-22. PubMed ID: 6774316
    [No Abstract]   [Full Text] [Related]  

  • 12. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
    Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
    Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of immuninhibitor hemophilia A with FEIBA plasma fraction].
    István L; Bariska I; Marton E
    Orv Hetil; 1980 Dec; 121(51):3131-5. PubMed ID: 6784062
    [No Abstract]   [Full Text] [Related]  

  • 14. Activated prothrombin concentrate for patients with factor VIII inhibitors.
    Kurczynski EM; Penner JA
    N Engl J Med; 1974 Jul; 291(4):164-7. PubMed ID: 4834485
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia A patient with inhibitor.
    Tourbaf KD; Dunlap BE; Ambrus JL; Rodman DJ; Atwal AJ
    J Med; 1982; 13(5-6):399-410. PubMed ID: 6820380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder.
    Brackmann HH; Gormsen J
    Lancet; 1977 Oct; 2(8044):933. PubMed ID: 72276
    [No Abstract]   [Full Text] [Related]  

  • 17. Characteristics and thrombogenicity of factor IX concentrate.
    Sakuragawa N; Takahashi K; Itoh M; Matsuoka M
    Bibl Haematol; 1977; 44():88-93. PubMed ID: 617788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of factor IX concentrate therapy in hemophilia.
    Hultin MB
    Blood; 1983 Sep; 62(3):677-84. PubMed ID: 6603880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in developing specific therapies for haemophilia.
    Ling G; Nathwani AC; Tuddenham EGD
    Br J Haematol; 2018 Apr; 181(2):161-172. PubMed ID: 29359795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Massive factor-VIII infusion in Haemophiliac with factor-VIII inhibitor, high responder. 1977.
    Brackmann HH; Gormsen J
    Haemophilia; 2010 May; 16(102):2-3. PubMed ID: 20536980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.